Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term adverse effects. Found 220 abstracts

no pagination
Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute. 2002 Dec 04;94(23):1773-9.
Pollack A, Horwitz EM. In regard to Sherertz et al., IJROBP 2001; 51:1241-1245 [letter]. Int J Radiat Oncol Biol Phys. 2002 Jun;53(2):512; author reply 512.
Russo IH. Cigarette smoking and risk of breast cancer in women. Lancet (London, England). 2002 Oct 05;360(9339):1033-4.
Russo J, Tahin Q, Lareef MH, Hu YF, Russo IH. Neoplastic transformation of human breast epithelial cells by estrogens and chemical carcinogens. Environmental and molecular mutagenesis. 2002 Jan;39(2-3):254-63.
Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, Perez CA, Roach M, Sandler HM, Pollack A, Cox JD. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1036-46.
Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002 Jun 15;20(12):2895-903.
Sun W, Stevenson JP, Gallo JM, Redlinger M, Haller D, Algazy K, Giantonio B, Alila H, O'Dwyer PJ. Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. Clin Cancer Res. 2002 Oct;8(10):3100-4.
Babb JS, Rogatko A. Patient specific dosing in a cancer phase I clinical trial. Statistics in medicine. 2001 Jul 30;20(14):2079-90.
Chao C, Torosian MH, Boraas MC, Sigurdson ER, Hoffman JP, Eisenberg BL, Fowble B. Local recurrence of breast cancer in the stereotactic core needle biopsy site: case reports and review of the literature. Breast J. 2001 Mar;7(2):124-7.
Cornfeld MJ, Jadwin A, O'Grady P, Babb J, Engstrom PF. Feasibility of assessing quality in medical oncology practices. Cancer Pract. 2001 Sep;9(5):231-5.
Desaulniers D, Leingartner K, Russo J, Perkins G, Chittim BG, Archer MC, Wade M, Yang J. Modulatory effects of neonatal exposure to TCDD, or a mixture of PCBs, p,p'-DDT, and p-p'-DDE, on methylnitrosourea-induced mammary tumor development in the rat. Environ Health Perspect. 2001 Jul;109(7):739-47.
Dorgan JF, Baer DJ, Albert PS, Judd JT, Brown ED, Corle DK, Campbell WS, Hartman TJ, Tejpar AA, Clevidence BA, Giffen CA, Chandler DW, Stanczyk FZ, Taylor PR. Serum hormones and the alcohol-breast cancer association in postmenopausal women. Journal of the National Cancer Institute. 2001 May 02;93(9):710-5.
Fleming GF, Fowler JM, Waggoner SE, Copeland LJ, Greer BE, Horowitz I, Sutton G, Schilder RJ, Fracasso PM, Ball HG, McGuire WP. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Feb 15;19(4):1021-9.
Giantonio BJ, Hochster H, Blum R, Wiernik PH, Hudes GR, Kirkwood J, Trump D, Oken MM. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs. 2001 Jan;19(1):89-92.
Hanks GE, Hanlon AL, Horwitz EM. Evidence for cure of 'young' men with prostate cancer. Oncology (Huntingt). 2001 May;15(5):563-7; discussion 571-4.
Held-Warmkessel J. Treatment of advanced prostate cancer. Semin Oncol Nurs. 2001 May;17(2):118-28.
Holland J. New treatment modalities in radiation therapy. J Intraven Nurs. 2001 Mar;24(2):95-101.
Knudson AG. Two genetic hits (more or less) to cancer. Nature reviews Cancer. 2001 Nov;1(2):157-62.
Meropol NJ, Niedzwiecki D, Hollis D, Schilsky RL, Mayer RJ. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr;91(7):1256-63.
Murphy BA, Leong T, Burkey B, Langer C, Forastiere A. Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393). Am J Clin Oncol. 2001 Feb;24(1):64-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term adverse effects

adverse effects Human Female Middle Age Adult Male US Gov't Support-PHS pathology Aged drug therapy therapeutic use Breast Neoplasms administration & dosage Drug Administration Schedule chemically induced Non-US Gov't Support Animal Antineoplastic Agents Prostatic Neoplasms radiotherapy Neoplasms Local Neoplasm Recurrence effects Neoplastic Cell Transformation analogs & derivatives adverse Drug Dose-Response Relationship etiology genetics methods pharmacology blood Age of Onset pharmacokinetics Radiotherapy secondary epidemiology Carcinogens Case-Control Studies Conformal Radiotherapy Disease Progression Antineoplastic Combined Chemotherapy Protocols Brachytherapy therapy Mutation 80 and over Aged Breast drug effects Feasibility Studies Radiation-Protective Agents Risk Factors Postmenopause administration & Intravenous Infusions Ovarian Neoplasms Odds Ratio Psychological Sexual Dysfunctions Polychlorinated Biphenyls Guideline Adherence Aneuploidy Thymidylate Synthase Radiation Dose-Response Relationship Uracil Lymphoma Neoplasm Seeding metabolism Prasterone Topotecan Research Design Health Care Quality Indicators Infiltrating Duct Carcinoma nursing Maximum Tolerated Dose Skin Neoplasms Sex Hormones Age Factors Environmental Pollutants Chromosome Aberrations Estrogen Replacement Therapy Interferon Inducers Rats Amifostine Questionnaires Matched-Pair Analysis surgery Dehydroepiandrosterone Sulfate Retinoblastoma Cisplatin Polylysine Remission Induction Leucovorin Oxidoreductases Chelating Agents Phosphodiesterase Inhibitors Dose Fractionation Carcinoma Granulocyte Colony-Stimulating Factor mortality Urinary Retention Kinetics Experimental Mammary Neoplasms Epidemiologic Research Design Protective Agents dosage Animal Disease Models Oncogenes Follow-Up Studies Radiometry Paclitaxel Thrombocytopenia Premenopause Retinoblastoma Genes Sprague-Dawley Rats Prospective Studies Treatment Outcome Organochlorine Insecticides cytology Defecation Mesna Radiotherapy Dosage Statistical Data Interpretation Adenocarcinoma Oral Administration Age Distribution Sulindac Population Surveillance DDT Kidney Neoplasms Antineoplastic Antimetabolites Peripheral Nerves Adolescent US Gov't Support-Non-PHS Fluorouracil Neoplasm Drug Resistance United States Women's Health Neutropenia Alkylating Agents BRCA2 Genes Androgen Antagonists Body Mass Index Tumor Suppressor Genes Poly I-C Ethanol Case Report BRCA1 Genes Adjuvant Chemotherapy Treatment Failure Heterozygote
Last updated on Wednesday, March 04, 2020